Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06770439RecruitingPhase 2
New drug plus chemotherapy for advanced pancreatic cancer
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18 years+ - NCT06762483Recruiting
Blood test for gene changes in advanced breast cancer
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Milan, ItalyAges 18 years+ - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT04209218Recruiting
Blood pressure and dexamethasone during lung cancer surgery
This study looks at how best to manage blood pressure during lung cancer surgery and whether giving dexamethasone (a steroid medicine) helps patients during the operation and recovery. You might benefit if you’re having longer lung cancer surgery and your heart and other organs are stable enough for the study.
Beijing, Beijing MunicipalityAges 50–90 - NCT06724016RecruitingPhase 1
Study of HM16390 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT06715501Enrolling by invitation
Testing cadonilimab with chemo and radiation for advanced esophageal cancer
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
Ningbo, ZhejiangAges 18–75 - NCT06716138RecruitingPhase 1
ANS03 for solid tumors with ROS1 or NTRK changes
This trial tests a new drug called ANS03 for people with certain genetic changes (ROS1 or NTRK) in their solid tumors. The goal is to see if ANS03 can shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT06356688RecruitingPhase 2
Study of chemo plus immunotherapy before surgery for esophageal cancer
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Nanjing, JiangsuAges 18–75 - NCT06356714RecruitingPhase 2
Nocardia cell wall skeleton plus current therapy for colorectal cancer
This trial tests adding an investigational drug (Nocardia rubra cell wall skeleton) to the current treatment for people with advanced colorectal cancer that is stable but showing early signs of getting worse. It aims to see if this combination can help delay further progression.
Nanjing, JiangsuAges 18 years+ - NCT06702891Recruiting
Exosome study of gastric cardia cancer
This study looks at tiny particles called exosomes from your cancer cells to better understand gastric cardia cancer. It may help doctors find new ways to diagnose or treat this type of stomach cancer.
Jinan, ShandongAges 18 years+ - NCT06195228RecruitingPhase 4
Real-world study of genetic types in advanced thyroid cancer
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
Fuzhou, FujianAges Any age - NCT06255392RecruitingPhase 3
Fluzoparib with apatinib vs chemo for advanced breast cancer
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
Guangzhou, GuangdongAges 18–70 - NCT06662760RecruitingPhase 1
TQB3002 for advanced cancers when standard treatments fail
This trial tests an experimental oral drug called TQB3002 for people with advanced solid tumors who have run out of standard options. Researchers are learning the best dose and how safe it is, with the hope of controlling or shrinking the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT06649292RecruitingPhase 3
Study of SHR-A1904 for gastric cancer with CLDN18.2
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Guangzhou, GuangdongAges 18–75 - NCT06648434RecruitingPhase 1
MK2 inhibitor plus mFOLFIRINOX for metastatic pancreatic cancer
This trial tests an experimental drug called zunsemetinib (an MK2 inhibitor) combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with pancreatic cancer that has spread to other organs. The goal is to see if the combination works better than chemotherapy alone.
St Louis, MissouriAges 18 years+ - NCT06638307RecruitingPhase 1
Study of new drug MEN2312 for advanced breast cancer with specific genetic changes
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
Springdale, ArkansasAges 18 years+ - NCT06616987RecruitingPhase 2
Preventing neutropenia from sacituzumab govitecan in TNBC
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
SeoulAges 19 years+ - NCT06597227Recruiting
Partial vs total stomach removal for upper stomach cancer after chemo
This trial compares two types of surgery for upper stomach cancer after chemotherapy or radiation. It aims to see if removing only part of the stomach (proximal gastrectomy) works as well as removing the whole stomach (total gastrectomy) to help you recover better.
Wuhan, HubeiAges 18–75 - NCT03878849RecruitingPhase 2
Study drug 2X-121 for ovarian cancer that keeps coming back
This Phase 2 trial tests whether 2X-121 can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy. It enrolls people who have had limited prior treatment and can provide a recent or stored tumor sample.
Oklahoma City, OklahomaAges 18 years+ - NCT06576115RecruitingPhase 2
Combination therapy with device for metastatic pancreatic cancer
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
Clarkston, MichiganAges 18 years+ - NCT06574880RecruitingPhase 1/Phase 2
Radiation and Lutetium PSMA for locally advanced prostate cancer
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
Cleveland, OhioAges 18 years+ - NCT05576480RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for rectal cancer without mismatch repair
This Phase 2 study tests penpulimab (an immunotherapy medicine) given with CAPEOX chemotherapy before surgery for rectal cancer that is “MSS” (not the mismatch-repair type). It aims to shrink the tumor and improve outcomes by treating before the operation.
Shanghai, None SelectedAges 18–75 - NCT06551220Recruiting
T-DXd for advanced breast cancer with various HER2 levels
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
New Haven, ConnecticutAges 18–80
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,550 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.